ArticleExperimental physiology2026
The role of orexin A in the pathogenesis of ischaemic stroke at high altitude.
Article in Experimental physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The neuropeptide in ischemic brain injury: insights, challenges, and horizon of targeted interventions.Journal of translational medicine · 2026Pooled it
- The orexin system as a pharmacological target in inflammation: peripheral mechanisms and safety implications.Frontiers in pharmacology · 2026Review
- The role of orexin A in the pathogenesis of ischaemic stroke at high altitude.Experimental physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Orexin offers protection against cerebral ischaemia-reperfusion injury, with high altitude playing a key role in modulating its expression. This study aimed to investigate the effect of high altitude on orexin expression and its pathophysiological mechanisms involved in high altitude stroke injury. In this study, changes of orexin expression were observed by simulating hypoxia at different altitudes, and the changes of orexin and its receptor were analysed by constructing a middle cerebral artery occlusion (MCAO) model after high altitude simulation. Finally, the protective effect of orexin on cerebral ischaemia-reperfusion injury was evaluated by exogenous orexin intervention. The results indicated that at an altitude of 4000 m, orexin expression was increased, but then decreased at higher altitudes. Rats exposed to 4000 m hypoxia simulation and MCAO exhibited increased orexin and type 1 receptor expression. Exogenous orexin A administration reduced infarct size, improved microcirculation blood flow in the ischaemic cortex, accelerated blood flow, elevated blood oxygen saturation and mitigated systemic oxidative stress and inflammation. These findings confirm our hypothesis that 4000 m altitude promotes orexin expression, thereby attenuating cerebral ischaemia-reperfusion injury through enhanced microcirculation, reduced oxidative stress and inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.